DDInter1266 DDInter1069
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin derived from _Escherichia coli_, the first natural ligand that activates GC-C. Linaclotide is used for the treatment of various types of constipation, including irritable bowel syndrome with constipation. Linaclotide was first approved by the FDA on August 30, 2012. It gained EMA and Health Canada approval on November 26, 2012 and December 3, 2013, respectively. Linaclotide works to improve the symptoms of constipation and gastrointestinal symptoms of conditions involving constipation.
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Desmopressin
Desmopressin {u} (Compound) resembles {v} (Compound) Linaclotide
Naproxen {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Terlipressin
Terlipressin {u} (Compound) resembles {v} (Compound) Linaclotide
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diclofenac
Diclofenac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etodolac
Etodolac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Naproxen {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Ketorolac
Ketorolac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Ketorolac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Naproxen {u} (Compound) causes {v} (Side Effect) Skin exfoliation
Skin exfoliation {u} (Side Effect) is caused by {v} (Compound) Etodolac
Etodolac {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Nabumetone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Picosulfuric acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Nabumetone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linaclotide
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin (Compound) resembles Linaclotide (Compound)
Naproxen (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Terlipressin (Compound) and Terlipressin (Compound) resembles Linaclotide (Compound)
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Etodolac and Etodolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Naproxen (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) resembles Ketorolac (Compound) and Ketorolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Naproxen (Compound) causes Skin exfoliation (Side Effect) and Skin exfoliation (Side Effect) is caused by Etodolac (Compound) and Etodolac may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Naproxen (Compound) resembles Nabumetone (Compound) and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Naproxen (Compound) resembles Nabumetone (Compound) and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Linaclotide